Savara (NASDAQ:SVRA) Trading Up 4.7% – What’s Next?

Savara Inc (NASDAQ:SVRA) rose 4.7% during mid-day trading on Tuesday . The company traded as high as $4.30 and last traded at $4.26. Approximately 40,619 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 1,197,658 shares. The stock had previously closed at $4.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday. HC Wainwright reduced their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Stock Down 15.1 %

The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average is $3.96 and its 200 day moving average is $4.22.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, analysts anticipate that Savara Inc will post -0.44 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Large investors have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co bought a new position in Savara during the first quarter valued at approximately $35,000. Choreo LLC acquired a new position in shares of Savara during the 2nd quarter worth $59,000. DRW Securities LLC bought a new position in shares of Savara during the 2nd quarter valued at $62,000. Principal Financial Group Inc. lifted its position in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.